NICE has recommended teduglutide (Revestive) in final draft guidance for people with short bowel syndrome who are aged 1 year and above and are in a stable condition following surgery to remove an abnormal bowel.

According to NICE final draft guidance, fenfluramine, when added to standard care medicines, reduces the number of convulsive seizures people have. It may also be more effective than cannabidiol plus clobazam in reducing the number of seizures when used with 2 other antiepileptic medicines.

The UK Health Security Agency has published background information and advice on coronavirus (COVID-19) for health and care professionals.

The MHRA has provided a positive EAMS scientific opinion for efgartigimod alfa in the treatment of myasthenia gravis.

NICE did not recommend esketamine due to limitations in the clinical evidence and economic model and has called for further research to address some of the uncertainties.